Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 34 results found. Search for [ Biocon covid-19 trials ]

Results 1 to 21 of 34
Reuters
March 1, 2021
Providing a final clearance for the vaccine a day after it was authorized by U.S. regulators, the Advisory Committee on Immunization Practices (ACIP) voted 12-0 to recommend the vaccine from J&J as appropriate for Americans 18 and older


BusinessToday.In
December 5, 2020
The 67-year-old BJP leader, who's also the home minister in the Khattar Cabinet, has requested everyone who might have come in his contact to get tested. He was the first volunteer in the phase three trials for Covaxin to get the vaccine shot


Manoj Sharma
November 27, 2020
New vaccines are rarely certified for efficacy above 90 per cent. Their efficacy improves as millions are vaccinated over decades. In fact, most vaccines get certified in the 40-60 per cent efficacy band


BusinessToday.In
November 24, 2020
On Monday, the rupee gained 5 paise to settle at more than two-week high of 74.11 per US dollar. The dollar index, which gauges the greenback's strength against a basket of six currencies, was down 0.04 per cent to 92.47


BusinessToday.In
November 24, 2020
India Stock Market Highlights Today: During the session, Sensex hit a lifetime high of 44,601 and Nifty touched record high of 13,079


BusinessToday.In
October 26, 2020
Sharing a BusinessToday.In report stating that the new nasal vaccine can be a game-changer for COVID-19 testing, Shaw tweeted that these inoculations will be far easier to deliver than intra muscular injections


PB Jayakumar
October 22, 2020
Serum Institute of India (SII) has teamed up with Merck KGaA, Germany, to develop COVID-19 fighting monoclonal antibodies (mAbs), made by cloning a unique white blood cell to increase immunity and fight diseases, along with drug research driven nonprofit scientific research organization IAVI and Scripps Research


BusinessToday.In
October 16, 2020
Mazumdar-Shaw said that India has a youthful population that has kept fatalities low. She also said that India fortunately has a large vaccine production capacity and that multiple firms are now holding clinical trials


BusinessToday.In
September 10, 2020
AstraZeneca on Wednesday \"voluntarily\" paused the phase 3 clinical trials after a volunteer developed an \"unexplained\" illness; in India, Serum Institute, one of the partners of University of Oxford, also decided to pause the trials following the DCGI notice


BusinessToday.In
New Delhi, September 4, 2020
Biocon executive chairperson Kiran Mazumdar-Shaw, who recently recovered from COVID-19, shared tips on how to fight the deadly virus. Talking about her experience, Shaw said that early testing allows early treatment and restricts it to mild illness. Watch the video for more.Also Read: AstraZeneca's COVID-19 vaccine enters human trials in Japan


BusinessToday.In
August 18, 2020
\"I have added to the Covid count by testing positive. Mild symptoms n I hope it stays that way,\" Kiran Mazumdar Shaw said in a tweet


BusinessToday.In
August 14, 2020
Much against Russia's claims of successfully registering world's first COVID-19 vaccine, India and the rest of the world have voiced serious concerns about its efficacy and safety


Kiran Mazumdar Shaw, Executive Chairperson, Biocon
New Delhi, August 5, 2020
Mining of huge data will enhance the probability of finding new drugs, making India the laboratory of the world


BusinessToday.In
July 31, 2020
Coronavirus vaccine news update: Biocon founder Kiran Mazumdar-Shaw said that the first doses of the vaccine should be administered to young people and health workers


PTI
July 24, 2020
Biocon said it plans to carry out a phase IV trial in 200 Covid-19 patients to know the therapeutic efficacy of Itolizumab across the country in 10-15 hospitals


BusinessToday.In
July 14, 2020
Biocon share has risen 7.78% in the last 5 days of gains. The stock opened with a gain of 2.03% and later touched an intraday high of Rs 435.25, rising 4.98% against yesterday's close of Rs 414.60 on BSE


BusinessToday.In
July 13, 2020
Last month, Cipla introduced Remdesivir under the brand name 'CIPREMI' after receiving approval from DCGI for \"restricted emergency use\" on adult and paediatric patients hospitalised with suspected or laboratory-confirmed COVID-19 infection


E Kumar Sharma
July 11, 2020
Coronavirus: Biocon founder and chairperson Kiran Mazumdar Shaw says that in a matter of about 120 days the company has moved from applying for commencement of trials on coronavirus patients to getting the final approval for commercialisation


PTI
July 11, 2020
The approval was given after its clinical trials on COVID-19 patients in India was found satisfactory by the expert committee


BusinessToday.In
July 3, 2020
Stock Market LIVE Updates on July 3: Bajaj Auto, followed by Asian Paints, Bharti Airtel, HUL, Reliance Industries, HUL and Kotak Bank were among the top gainers in the Sensex pack. On the contrary, Tata Steel, HDFC, M&M and Bajaj Finance were among the laggards


PAGES 1 OF 2  12